rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Protara Therapeutics, Inc.

TARA · Nasdaq

Health CareBiotechnologyNot moving yet

TARA stood above a rising 150-day average in 21 of the last 52 weekly readings, and has been out of that trend for the last 31 weeks. It is 44.9% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 31
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$2.0M
Officials’ trades on record
0
Institutions holding
119 (+8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 21 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.7M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 2
WhoDidSharesTraded
Jesse SheffermanCEO and Presidentsold215,687at $4.0929 Jun 2026filed 1 Jul 2026
Jacqueline ZummoChief R&D Officersold1,134at $5.408 Apr 2026filed 9 Apr 2026
Jacqueline ZummoChief R&D Officersold22,598at $5.261 Apr 2026filed 2 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders119+8 on the quarter
New · exited28 · 19
Reported value$176.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Jupiter Topco LLCnew · filed 14 Aug 20264,696,709$17.9M+4,696,709
BlackRock, Inc.added · filed 7 Aug 20263,663,499$14.0M+268,531+7.9%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20263,101,166$11.8M+269,958+9.5%
Velan Capital Investment Management LPadded · filed 14 Aug 20262,844,652$10.9M+10,000+0.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,300,133$8.8M+181,115+8.5%
Blackstone Inc.unchanged · filed 14 Aug 20262,265,514$8.7M00.0%
ORBIMED ADVISORS LLCnew · filed 14 Aug 20262,220,000$8.5M+2,220,000
Sio Capital Management, LLCreduced · filed 14 Aug 20261,921,872$7.3M-47,967−2.4%
ACORN CAPITAL ADVISORS, LLCunchanged · filed 14 Aug 20261,752,115$6.7M00.0%
Integral Health Asset Management, LLCreduced · filed 14 Aug 20261,500,000$5.7M-250,000−14.3%
31 Mar 2023 – 30 Jun 2026
2772116Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Jesse Shefferman Company insiderCEO and President · last 30 Jun 20261 · 1
Barry P. Flannelly Company insiderDirector · last 15 Jun 20260 · 0
Cynthia Smith Company insiderDirector · last 15 Jun 20260 · 0
Gregory Sargen Company insiderDirector · last 15 Jun 20260 · 0
Jane Huang Company insiderDirector · last 15 Jun 20260 · 0
Luke M. Beshar Company insiderDirector · last 15 Jun 20263 · 0
Michael Edward Solomon Company insiderDirector · last 15 Jun 20260 · 0
Richard S. Levy Company insiderDirector · last 15 Jun 20262 · 0
Roger Garceau Company insiderDirector · last 15 Jun 20260 · 0
William Conkling Company insiderChief Commercial Officer · last 2 Jun 20260 · 0
Jacqueline Zummo Company insiderChief R&D Officer · last 8 Apr 20260 · 3
Hannah Fry Company insiderVP, Controller · last 26 Jan 20260 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-32.5%
Share count trendFY 2025 · to 5 Mar 20260.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$49.7M
Free cash flowFY 2025 · to 31 Dec 2025−$56.5M

Analyst forecasts

No analyst forecasts yet.